Skip to content

US Dept of Defense – Melanoma Research Program

Home / Funding Opportunity / US Dept of Defense – Melanoma Research Program

US Dept of Defense – Melanoma Research Program


Idea AwardHT9425-23-MRP-IA

  • up to USD$500,000 over 3 years
  • Pre-proposals due 10 July 2023
  • Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research that are beyond an incremental advancement.
  • Emphasis on innovation and impact.
  • PIs new to the melanoma field are encouraged
  • preliminary data discouraged
  • clinical trials not allowed
  • must address at least one MRP focus area

Melanoma Academy Scholar Award –

  • up to USD$550,000 over 3 years
  • letters of intent due 31 August 2023
  • Supports the addition of new Scholars to the unique, interactive virtual Melanoma Academy that provides intensive mentoring, national networking, collaborations, and a peer group for early-career melanoma investigators.
  • must be within 7 years of first faculty-level appointment
  • Requires a Career Guide who is an experienced melanoma researcher with melanoma cancer funding, does not have to be a the same insititution
  • preliminary data not required
  • clinical trials not allowed
  • must address at least one MRP focus area


Mid-Career Accelerator AwardHT9425-23-MRP-MCAA

  • up to USD$725,000 over 3 years
  • letters of intent due 31 August 2023
  • Supports mid-career researchers conducting impactful melanoma research.
  • must be Assistant or Assoc Prof (or equivalent) at least 7 years from first faculty-level appointment.  must show evidence of at least one peer-reviewed source of external funding
  • preliminary data relevant to melanoma required
  • clinical trials not allowed
  • must address at least one MRP focus area

Team Science Award

  • up to USD$1.25M over 3 years
  • letters of intent due 31 August 2023
  • Supports new or existing partnerships to address a research problem or question in a manner that would be unachievable through separate efforts.
  • At least two and up to three Investigators must partner in one overarching
    multidisciplinary research study.  Independent investigators must be at level of Assistant Professor (or equivalent) or above
  • Inclusion of at least one military, US Department of Veterans Affairs, or ECR or is encouraged.  Postdoctoral fellows are not eligible to be Initiating nor Partnering PIs.
  • Intended to fund a broad range of studies including, but not limited to:
    • Correlative studies that associated with an open/ongoing or completed clinical trial
    • Research involving analysis of large and/or complex melanoma datasets
    • Projects focusing on bioengineering approaches to address diagnostics, high risk markers, dormancy, and/or metastasis
    • Research seeking to better understand and/or reduce inequities and disparities that impact melanoma patients and/or caregivers.
  • Emphasis on synergy, multidisciplinary research, and impact.
  • Applicants are encouraged but not required to collaborate with the melanoma community
  • Preliminary data required
  • clinical trials not allowed
  • must address at least one MRP focus area

Focused Program Award – Rare Melanomas

  • up to USD$2M over 4 years
  • letters of intent due 31 August 2023
  • Supports a synergistic, multidisciplinary research program of at least two but not more than three distinct but complementary projects addressing an overarching question relevant to rare melanomas.
  • Applications may propose projects across the entire research spectrum (biology, etiology, prevention, diagnosis and detection, prognosis, treatment, and quality of life) and must address a critical unmet need relevant to rare melanomas (uveal, acral, mucosal, pediatric etc).
  • Individual research projects may range from exploratory, hypothesis-developing studies through clinical trials
  • Applicants are encouraged, but not required, to collaborate with the rare melanoma community
  • clinical trials allowed

MRP Focus Areas


  • Identify and understand risk factors and biomarker determinants for melanoma, including rare subtypes.
  • Develop prediction and surveillance tools for distinguishing patient populations and/or early tumors at risk for second primary, recurrence, metastasis, and/or treatment toxicity.
  • Develop new tools for the detection of melanoma, which includes easily accessible technology (beyond the dermoscope) for primary care physicians, dermatologists, oncologists, and/or pathologists.
  • Understand how precursor lesions evolve, and/or how environmental/endogenous factors influence melanomagenesis and/or early dissemination.
  • Identify how the tumor microenvironment and/or microbiome impacts tumor initiation, response to therapy, progression, recurrence, and/or dormancy.
  • Delineate the cellular and/or molecular mechanisms that influence metastatic spread (eg site-specific adaptations), recurrence, and/or dormancy.
  • Develop new preclinical models of melanomagenesis, early dissemination, and progression that more faithfully represent the disease progression observed in humans.

Rare Melanoma

  • Address unmet needs across the entire cancer research spectrum (biology, etiology, prevention, early diagnosis and detection, prognosis, treatment, and survivorship) for rare melanomas


  • Address the physical and psychological impacts of a melanoma diagnosis, symptom trajectories, adverse effects of treatment, and other outcomes that affect individuals with melanoma and their family members.

Read more

Supporting documents

Refence Table of Award Mechanisms: 23mrpreftable

Idea Award: HT9425-23-MRP-IA-GG

Melanoma Academy Scholar Award: HT9425-23-MRP-MASA-GG

Mid-Career Accelerator Award:HT9425-23-MRP-MCAA-GG

Team Science Award: HT9425-23-MRP-TSA-GG

Focused Program Award – HT9425-23-MRP-FPA-RM-GG

You may be also interested in ...